277 related articles for article (PubMed ID: 25975389)
41. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
[TBL] [Abstract][Full Text] [Related]
42. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
43. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
44. Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells.
Jung CY; Kim SY; Lee C
Anticancer Res; 2018 Jan; 38(1):279-286. PubMed ID: 29277784
[TBL] [Abstract][Full Text] [Related]
45. The TAM Subfamily of Receptor Tyrosine Kinases: The Early Years.
Prieto AL; Lai C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542343
[TBL] [Abstract][Full Text] [Related]
46. AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
Rankin EB; Fuh KC; Taylor TE; Krieg AJ; Musser M; Yuan J; Wei K; Kuo CJ; Longacre TA; Giaccia AJ
Cancer Res; 2010 Oct; 70(19):7570-9. PubMed ID: 20858715
[TBL] [Abstract][Full Text] [Related]
47. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
48. [Tyro3 and CDK9 as biomarkers for drug resistance to breast cancer anti-PD-1 therapies].
Zhang JF; Liu T
Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):651-656. PubMed ID: 37580269
[No Abstract] [Full Text] [Related]
49. Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma.
Li Y; Wang X; Bi S; Zhao K; Yu C
Biochem Biophys Res Commun; 2015 Feb; 457(3):461-6. PubMed ID: 25596315
[TBL] [Abstract][Full Text] [Related]
50. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
51. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.
Seitz HM; Camenisch TD; Lemke G; Earp HS; Matsushima GK
J Immunol; 2007 May; 178(9):5635-42. PubMed ID: 17442946
[TBL] [Abstract][Full Text] [Related]
52. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
53. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
[TBL] [Abstract][Full Text] [Related]
54. Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells.
Lu Y; Wan J; Yang Z; Lei X; Niu Q; Jiang L; Passtoors WM; Zang A; Fraering PC; Wu F
FASEB J; 2017 Apr; 31(4):1382-1397. PubMed ID: 28034848
[TBL] [Abstract][Full Text] [Related]
55. AXL in cancer: a modulator of drug resistance and therapeutic target.
Tang Y; Zang H; Wen Q; Fan S
J Exp Clin Cancer Res; 2023 Jun; 42(1):148. PubMed ID: 37328828
[TBL] [Abstract][Full Text] [Related]
56. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
[TBL] [Abstract][Full Text] [Related]
57. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Dufour F; Silina L; Neyret-Kahn H; Moreno-Vega A; Krucker C; Karboul N; Dorland-Galliot M; Maillé P; Chapeaublanc E; Allory Y; Stransky N; Haegel H; Menguy T; Duong V; Radvanyi F; Bernard-Pierrot I
Br J Cancer; 2019 Mar; 120(5):555-564. PubMed ID: 30765874
[TBL] [Abstract][Full Text] [Related]
58. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
59. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
[TBL] [Abstract][Full Text] [Related]
60. NGF-induced Tyro3 and Axl function as survival factors for differentiating PC12 cells.
Zheng Y; Zhang L; Lu Q; Wang X; Yu F; Wang X; Lu Q
Biochem Biophys Res Commun; 2009 Jan; 378(3):371-5. PubMed ID: 19027714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
